Matinas Biopharma Holdings Inc (MTNB) Earnings Report, Financial Results, Financial analysis

Matinas Biopharma Holdings Inc increased first quarter of 2023 net loss per share of $-0.03 compare to net loss per share of $-0.03 recorded in the same quarter a year ago a decrease compare to $-0.01 realized in previous quarter.

*first quarter of 2023*
Earnings Per Share	Revenues
$ -0.03	$ 1 Mill
Unch.	$+1M

Matinas Biopharma Holdings Inc 's Revenue rose by 0 % in first quarter of 2023 (Mar 31 2023) year on year, to $1 million and advanced by 3.1 % sequentially.

Matinas Biopharma Holdings Inc is Expected to report next financial results on August 10, 2023.

More on MTNB's Income Statement

MTNB's NET INCOME

Matinas Biopharma Holdings Inc 's in thefirst quarter of 2023 recorded net loss of $-5.513 million, an improvement compare to net loss of $-6.699 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on MTNB's Growth

Matinas Biopharma Holdings Inc Inventories
In Mar 31 2023 company's net cash and cash equivalents decreased by $-1 million

Earnings quality

Matinas Biopharma Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Matinas Biopharma Holdings Inc payed $ -0.04 cash per share, on a free-cash flow basis .

Book value fell by -5.74 % sequentially to $0.15 per share, -8.95% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.13 per share from $ 0.14.

Company repurchased 12.72 million shares or 5.53 % in Mar 31 2023.

• More on MTNB's Dividends

Market Capitalization (Millions)	81
Shares Outstanding (Millions)	217
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	4
Net Income (TTM) (Millions $)	-20
Cash Flow (TTM) (Millions $)	-24
Capital Exp. (TTM) (Millions $)	-1
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	230

Earnings quality

Matinas Biopharma Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Matinas Biopharma Holdings Inc had negative $ -0.04 cash flow per share, on a free-cash flow basis .

Book value fell by -5.74 % sequentially to $0.15 per share, -8.95% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.13 per share from $ 0.14.

Company repurchased 12.72 million shares or 5.53 % in Mar 31 2023.

• More on MTNB's Balance Sheets

Market Capitalization (Millions)	81
Shares Outstanding (Millions)	217
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	4
Net Income (TTM) (Millions $)	-20
Cash Flow (TTM) (Millions $)	-24
Capital Exp. (TTM) (Millions $)	-1
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	230

Matinas Biopharma Holdings Inc

MTNB's Financial Statements and Analysis